Search Results
Your search for this matches 25363 pages
Showing 11401 - 11450Targeting an Important Tumor Vulnerability With Maintenance Olaparib in Germline BRCA-Mutated Pancreatic Cancer
In the POLO trial, which is discussed in this issue of The ASCO Post, Golan and colleagues evaluated the potential benefit of maintenance olaparib after disease stability or response to a minimum of 4 months of platinum-based chemotherapy in patients with metastatic pancreatic cancer and a...
ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy
Findings from the randomized phase III NRG Oncology/RTOG 9601 trial were initially reported in 2017, and showed that the addition of 2 years of antiandrogen therapy to postsurgical radiation treatment for men with recurrent prostate cancer increased their long-term overall survival rate. That study ...
ASTRO 2019: Machine-Learning Model May Accurately Predict Radiation Side Effects in Patients With Head and Neck Cancers
A study by Reddy et al investigating the use of a machine-learning model to predict which patients with head and neck cancer being treated with radiation may experience significant weight loss, feeding tube placement, and unplanned hospitalization has found that the model accurately identified the...
Bevacizumab/Niraparib vs Niraparib Alone for Platinum-Sensitive Recurrent Ovarian Cancer
In the phase II NSGO-AVANOVA2/ENGOT-ov24 trial reported in The Lancet Oncology, Mansoor Raza Mirza, MD, and colleagues found that the combination of bevacizumab plus niraparib prolonged progression-free survival vs niraparib alone in women with platinum-sensitive recurrent ovarian cancer. Study...
FDA Issues Drug Safety Communication on Lung Inflammation Due to Treatment With CDK4/6 Inhibitors
On September 13, the U.S. Food and Drug Administration (FDA) issued a drug safety communication warning that palbociclib, ribociclib, and abemaciclib—used to treat some patients with advanced breast cancer—may cause rare but severe inflammation of the lungs. The agency approved new warnings about...
Conundrums in Managing Cancer-Associated Thrombosis
Although there may be a clear role for prophylactic anticoagulation in hospitalized patients and those undergoing surgery, indication for prophylactic anticoagulation for patients with cancer seen in the ambulatory setting has yet to emerge. Until clinical trial data on prophylactic...
ASTRO 2019: Effect of Closure of Women’s Health Clinics From 2010 to 2013 on Cervical Cancer Screening and Detection
Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer; more women were diagnosed with advanced stages of the disease; and disease mortality rates rose. Findings from a new analysis combining several...
ASTRO 2019: ORIOLE Trial: Observation vs SABR for Oligometastatic Prostate Cancer
The randomized, phase II ORIOLE trial studying the efficacy of targeted high-dose radiation for men with oligometastatic prostate cancer has shown that stereotactic ablative radiation (SABR) is an effective and safe option for patients who wish to delay hormone-suppression therapy. Data from the...
Chef Uses Flavor to Fuel Her Mother’s Appetite During Cancer Treatment
The battle against cancer is typically waged by the surgeon and oncologist, but a Lexington, Kentucky–based, award-winning restaurateur and chef discovered her role as a foot soldier when she applied her culinary skills to deal with the debilitating side effects of her mother’s lung cancer...
News From the IASLC World Conference on Lung Cancer and the ASCO Quality Care Symposium
This week, we’ll be discussing findings presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer and the ASCO Quality Care Symposium, including a pooled analysis on 5-year overall survival rates in patients with previously treated non-small...
WCLC 2019: Selpercatinib in RET Fusion–Positive NSCLC
Patients with RET fusion–positive non–small cell lung cancer (NSCLC) comprise up to 2% of all NSCLC cases, but there are no targeted therapies currently approved for patients with this form of lung cancer. Selpercatinib (also known as LOXO-292) is an oral and highly selective investigational drug...
Liquid Biopsy to Determine Patient Response to Immune Checkpoint Blockade
Although studies have demonstrated that microsatellite instability (MSI) and high tumor mutational burden (TMB) are promising pan-tumor biomarkers for identifying patients for treatment with immune checkpoint blockade, obtaining tissue from unresectable or metastatic solid tumors for genetic...
Neoadjuvant Cisplatin/Gemcitabine Followed by Standard Chemoradiation in Locally Advanced Cervical Cancer
In a Brazilian single-center phase II trial reported in the Journal of Clinical Oncology, da Costa et al found that neoadjuvant cisplatin/gemcitabine followed by standard chemoradiation therapy with cisplatin did not improve outcomes vs chemoradiation therapy alone in locally advanced cervical...
WCLC 2019: Declaration From IASLC on Tobacco Cessation After Cancer Diagnosis
The International Association for the Study of Lung Cancer (IASLC) used the platform of the 2019 World Conference on Lung Cancer (WCLC) to call attention to the importance of tobacco cessation after cancer diagnosis and urged all physicians to screen patients with cancer for tobacco use and...
Michael Kenneth Keng, MD, on an ASCO Quality Training Program: 5-Year Review
Michael Kenneth Keng, MD, of the University of Virginia, gives a status update on this international program, and discusses future initiatives which include coaching mentorship and publishing articles on quality care (Abstract 7).
Joseph O. Jacobson, MD, on Suffering, Systems, and Safety: The Joseph V. Simone Award Lecture
Joseph O. Jacobson, MD, of Dana-Farber Cancer Institute, and this year’s recipient of the award for excellence in quality cancer care, discusses the need for quality improvement (QI) to encompass systems of care, the role of QI in preventing suffering, how poor quality affects patient safety, and...
Oncology Communications Online: Pause and Think Before Hitting ‘Send’
The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...
WCLC 2019: Screening Efficacy of PLCOm2012 vs USPSTF Criteria
Researchers reported that a prospective trial comparing two screening methods for patients at risk of developing lung cancer found that a model used by Canadian, Australian, and European public health organizations detected more cancers than the screening model used by the United States Preventive...
T-DM1 Plus Neratinib in Metastatic HER2-Positive Breast Cancer
In the phase Ib NSABP Foundation Trial FB-10 reported in the Journal of Clinical Oncology, Jame Abraham, MD, and colleagues found evidence of activity of the combination of ado-trastuzumab emtansine (T-DM1) plus neratinib in metastatic HER2-positive breast cancer and identified the dose of the...
Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer
Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant improvements in overall response rate and progression-free survival in women with germline...
WCLC 2019: Survey Findings on Evidence-Based Guidelines for Molecular Testing in Lung Cancer
One-third of those who responded to a survey reported they are unaware of evidence-based guidelines that support the use of molecular testing in lung cancer, according to results from the International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung...
2019 Lasker Awards for Basic and Clinical Medical Research and Public Service Announced
On September 10, The Lasker Foundation announced the winners of its 2019 Lasker Awards: Max D. Cooper, MD, of Emory University, and Jacques Miller, AC, FRS, FAA, of the Walter and Eliza Hall Institute of Medical Research, will receive the Albert Lasker Basic Medical Research Award; H. Michael...
WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC
The addition of durvalumab to chemotherapy improved overall survival in patients with extensive-stage small cell lung cancer (SCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) (Abstract PL02.11)....
FDA Proposes New Required Health Warnings With Images for Cigarette Packages and Advertisements
On August 15, the U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and in advertisements to promote greater public understanding of the negative health consequences of smoking. The proposed warnings, which feature photo-realistic...
Circulating Tumor DNA and Relapse in Early-Stage Breast Cancer
In a study reported in JAMA Oncology, Nicholas C. Turner, PhD, and colleagues found that detection of circulating tumor DNA (ctDNA) during follow-up after initial treatment for early breast cancer was associated with a high risk of relapse. Detection at diagnosis was also associated with poorer...
Combined Use of Identification Methods for Dense Breasts and Discussion of Supplemental Imaging
In a study reported in JAMA Internal Medicine, Karla Kerlikowske, MD, and colleagues found that the combined use of Breast Imaging Reporting and Data System (BI-RADS) breast density and Breast Cancer Surveillance Consortium (BCSC)-defined risk for breast cancer may be an effective way of...
HIV-Positive Older Adults With Cancer and Worsened Disease Outcomes
In a study reported in JAMA Oncology, Anna E. Coghill, PhD, MPH, and colleagues found that outcomes are often worse among human immunodeficiency virus (HIV)-positive patients aged 65 years or older with cancer vs HIV-negative patients with cancer, after adjustment for first courses of treatment....
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Having Cancer as a Teenager Derailed My Life Course
In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...
A Vigorous Life Through the Prism of Impending Death
“Live while you’re living, friends,” writes Julie Yip-Williams in her memoir, The Unwinding of the Miracle: A Memoir of Life, Death, and Everything That Comes After. It was The New York Times bestseller when she died of stage IV colon cancer at the age of 42. She is the most recent of several...
Not for the Squeamish: Surgery in the 19th Century
Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...
Pembrolizumab in Advanced Esophageal Squamous Cell Cancer With PD-L1 Expression of CPS ≥ 10
On July 30, 2019, pembrolizumab was approved for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed cell death ligand 1 (PD-L1; Combined Positive Score [CPS] ≥ 10), as determined by a U.S. Food and Drug...
Pembrolizumab in First-Line Treatment of Head/Neck Squamous Cell Carcinoma
On June 10, 2019, pembrolizumab was approved for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.1,2 Pembrolizumab was approved for use in combination with platinum and fluorouracil (5-FU) for all patients and as a single agent...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Insightful Advice From a College Advisor Leads to an Unexpected Career in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Tatiana M. Prowell, MD, who currently serves as Associate Professor of Oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center and as a Medical Officer and...
Confronting the Criticisms Facing Watson for Oncology
Over the past 2 years, IBM’s Watson for Oncology cognitive computing system, which uses artificial intelligence (AI) algorithms to generate treatment recommendations, has come under fire for allegedly not delivering on expectations to provide state-of-the-art personalized treatment for patients...
MD Anderson to Expand Proton Therapy Center
The University of Texas MD Anderson Cancer Center recently unveiled plans to expand its Proton Therapy Center. The expansion will more than double the center’s size to more than 160,000 square feet. The estimated completion of the new building is November 2023. The $159 million expansion will...
FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...
Firing Your Patient: How to Terminate a Treatment Relationship
Many clinicians are confused by the evolving opioid prescribing guideline issued by the Centers for Disease Control and Prevention (CDC) meant to stem the rising epidemic of opioid addiction and overdose in the United States.1 Many are also worried about regulatory oversight by the U.S. Drug...
Bert Vogelstein, MD, and Irving L. Weissman, MD, Recognized for Revolutionizing Cancer Research
Two scientists, whose discoveries in stem cell and cancer cell biology have led to innovative advances in fields ranging from oncology and immunology to cancer genomics and regenerative medicine, will receive the 2019 Albany Medical Center Prize in Medicine and Biomedical Research. Bert Vogelstein, ...
Women Who Conquer Cancer: Featured Conversations
The Conquer Cancer “Your Stories” mini-podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. Developed by Conquer Cancer, the series also includes transcripts of conversations. In one such featured conversation, Christina...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, has funded 21 Young...
ASCO Welcomes 2019–2020 Leadership Development Program Participants, Education Scholars
ASCO is pleased to announce the 2019–2020 participants in its Leadership Development Program and Education Scholars Program. Leadership Development Program The ASCO Leadership Development Program, which began in 2009, is a year-long program designed to train future leaders in oncology by supporting ...
New ASCO Ethical Framework for Including Research Biopsies in Clinical Trials
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials. The framework, published in a statement in the Journal of Clinical Oncology on July 25, provides guidance on when to include optional and mandatory biopsies based on both participant ...
Sita Kugel, PhD, Receives Grant to Study Aggressive Type of Pancreatic Cancer
The deadly nature of most pancreatic tumors is well known, with less than 10% of patients with pancreatic ductal adenocarcinoma estimated to survive 5 years after diagnosis. Recent molecular analyses of pancreatic ductal adenocarcinoma have shown that a patient’s prognosis changes depending on the...
Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD, Receive Endowed Chairs at Fred Hutchinson Cancer Research Center
Two researchers at the Fred Hutchinson Cancer Research Center in Seattle were recently awarded endowed chairs: Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD. Raisbeck Endowed Chair for Collaborative Research Dr. Davidson was awarded the Raisbeck Endowed Chair for Collaborative Research at Fred ...
Primary Central Nervous System Lymphoma: Striving for a Curative Therapy
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established. In light of recent insights into its pathophysiology and the emergence of novel approaches, The ASCO Post asked Tracy T. Batchelor, MD, a specialist in...
CureMD Oncology Integrates NCCN Templates
The National Comprehensive Cancer Network® (NCCN®) is collaborating with CureMD to integrate the NCCN Chemotherapy Order Templates into the CureMD Oncology electronic health records. This collaboration is intended to allow for point-of-care access to treatment recommendations and order templates...
$1 Million Gift for Epithelioid Hemangioendothelioma Research
The Epithelioid Hemangioendothelioma (EHE) Foundation and Cleveland Clinic recently received a $1 million gift from the Margie and Robert E. Petersen Foundation. The money will support EHE research conducted by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine ...
IU Simon Cancer Center Earns NCI’s Comprehensive Cancer Center Designation
The Indiana University Melvin and Bren Simon Cancer Center (IU Simon Cancer Center) has achieved the highest recognition from the National Cancer Institute (NCI): Comprehensive Cancer Center. With this federal designation signifying research excellence, it becomes the only NCI-designated...
